Intravitreal injections of ziv-aflibercept

PreclinicalProtein / enzyme

Intravitreal injections of ziv-aflibercept is one of 5 small molecule programs targeting Intravitreal Injections. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intravitreal InjectionsCompleted

Intravitreal InjectionsPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Intravitreal Injections

#DrugCompanyPhaseTrials

IRX-101

IiRenix Medical, Inc.

Phase 3

1 2

Ophthaine

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 3

Anti-VEGF Agents

SSt. Olavs Hospital

Preclinical

1 4

Intravitreal injections of ziv-aflibercept

RRetina Clinic, Sao Paulo, Brazil

Preclinical

1 5

Optive

IInnovative Medical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intravitreal Injections1 trial

Intravitreal Injections of Ziv-aflibercept for Macular Diseases

Completed·RRetina Clinic, Sao Paulo, Brazil·N/A·NCT02556723·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravitreal injections of ziv-aflibercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal injections of ziv-aflibercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal injections of ziv-aflibercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Retina Clinic, Sao Paulo, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: RRetina Clinic, Sao Paulo, Brazil

Intravitreal injections of ziv-aflibercept

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intravitreal Injections1 trial

References

Drug Info

Quick Facts

Related News